Patient‐derived tumor organoids (PDOs), patient‐derived xenografts (PDXs), and patient cohorts analysis suggested that MCB1 levels in HCCs may determine the distinct responses to conventional therapeutics and targeted drugs. The gene discussed is PSMD4; the disease is neoplasm.